Literature DB >> 24083948

Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method.

Katiany R Caleffi-Ferracioli1, Flaviane G Maltempe, Vera Lúcia D Siqueira, Rosilene F Cardoso.   

Abstract

Tuberculosis (TB) is a health public problem and a long combination therapy is necessary to treat patients. In recent years, some drugs, not routinely used in treatment of TB, have appeared as promising new anti-TB therapies in patients with resistance to classical drugs. The aim of this study was: (i) to evaluate a modified checkerboard assay, Resazurin drugs combination microtiter assay (REDCA) to detect drugs interaction in Mycobacterium tuberculosis; (ii) to evaluate the interaction between isoniazid (INH) or ethambutol (EMB) with levofloxacin (LEVO) in susceptible and resistant M. tuberculosis Brazilian clinical isolates. M. tuberculosis H37RV ATCC 27294 and 19 clinical isolates (10 resistant and 9 susceptible) were tested. The fractional inhibitory concentration index (FICI) ≤ 0.5 was considered synergistic. Synergism in M. tuberculosis H37RV and resistant M. tuberculosis Brazilian isolates was observed with EMB vs. LEVO. No synergism was observed with INH vs. LEVO by both assays. No statistical difference was observed by the two assays studied. REDCA showed to be a simple assay for detecting synergism between drugs in M. tuberculosis. The results with EMB vs. LEVO are promising and it can be a new option in future investigations of drugs interactions against M. tuberculosis with the view to reduce EMB adverse effects.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drugs; Mycobacterium tuberculosis; REDCA; Synergism

Mesh:

Substances:

Year:  2013        PMID: 24083948     DOI: 10.1016/j.tube.2013.09.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  6 in total

1.  Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus.

Authors:  Rose C Lopeman; James Harrison; Daniel L Rathbone; Maya Desai; Peter A Lambert; Jonathan A G Cox
Journal:  Sci Rep       Date:  2020-01-27       Impact factor: 4.379

2.  Total Synthesis of Tetrahydrolipstatin, Its Derivatives, and Evaluation of Their Ability to Potentiate Multiple Antibiotic Classes against Mycobacterium Species.

Authors:  Saniya S Khan; Thanuja D Sudasinghe; Alexander D Landgraf; Donald R Ronning; Steven J Sucheck
Journal:  ACS Infect Dis       Date:  2021-09-03       Impact factor: 5.578

3.  In vitro activity of rifampicin and verapamil combination in multidrug-resistant mycobacterium tuberculosis.

Authors:  Fernanda de Oliveira Demitto; Renata Claro Ribeiro do Amaral; Flaviane Granero Maltempe; Vera Lúcia Dias Siqueira; Regiane Bertin de Lima Scodro; Mariana Aparecida Lopes; Katiany R Caleffi-Ferracioli; Pedro Henrique Canezin; Rosilene Fressatti Cardoso
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

4.  In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant Mycobacterium tuberculosis Isolated from Retreatment Tuberculosis Patients.

Authors:  Ruoyan Ying; Xiaochen Huang; Yaxian Gao; Jie Wang; Yidian Liu; Wei Sha; Hua Yang
Journal:  Infect Drug Resist       Date:  2021-09-14       Impact factor: 4.003

5.  Rifampin- or Capreomycin-Induced Remodeling of the Mycobacterium smegmatis Mycolic Acid Layer Is Mitigated in Synergistic Combinations with Cationic Antimicrobial Peptides.

Authors:  DeDe Kwun-Wai Man; Tokuwa Kanno; Giorgia Manzo; Brian D Robertson; Jenny K W Lam; A James Mason
Journal:  mSphere       Date:  2018-07-18       Impact factor: 4.389

Review 6.  Pre-Clinical Tools for Predicting Drug Efficacy in Treatment of Tuberculosis.

Authors:  Hasmik Margaryan; Dimitrios D Evangelopoulos; Leticia Muraro Wildner; Timothy D McHugh
Journal:  Microorganisms       Date:  2022-02-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.